Drugs / KT-253
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05775406 | May 2023 → Dec 2024 | acute lymphoblastic leukemia, cancer, myeloid neoplasm | Kymera Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KT-253 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05775406 ↗ |
| Route | Intravenous | “administered intravenously” NCT05775406 ↗ |